Revolutionizing Atopic Dermatitis

Sarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.

A poster from the RAD Virtual Conference reviewed the relationship between Black and DHH patients and the shared disparities these populations face.

David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

A poster presented at the 2023 ReV Virtual Conference explored the association between the 2 conditions.

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference.

Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.

Catch up on all coverage from Revolutionizing Atopic Dermatitis.

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.